(Q44574410)

4 December 2017

title

Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover (English)

1 reference

4 December 2017

0 references

0 references

N A Darmani

1

1 reference

4 December 2017

J J Janoyan

series ordinal

2

1 reference

4 December 2017

N Kumar

series ordinal

3

1 reference

4 December 2017

J L Crim

series ordinal

4

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

Pharmacology, Biochemistry and Behavior

4 December 2017

published in

1 reference

4 December 2017

volume

75

1 reference

4 December 2017

issue

4

1 reference

4 December 2017

page(s)

777-787

1 reference

Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A.

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Behavioral effects of cannabinoid agents in animals

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Cannabinoid modulation of intestinal propulsion in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Serotonin 5-HT3 receptor antagonists prevent cisplatin-induced emesis in Cryptotis parva: a new experimental model of emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

The CB1 cannabinoid receptor antagonist SR 141716A affects A9 dopamine neuronal activity in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Habenula lesions decrease the responsiveness of dorsal raphe serotonin neurons to cocaine.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Pharmacology of cannabinoid CB1 and CB2 receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Cannabis and cannabinoids: pharmacology and rationale for clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Systemic uptake inhibition decreases serotonin release via somatodendritic autoreceptor activation

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Neuroendocrine response to L-5-hydroxytryptophan challenge in prepubertal major depression. Depressed vs normal children

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Modulation of transmitter release via presynaptic cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Inhibitory effects of SR141716A on G-protein activation in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

A comparison of the behavioural effects of 5-HT2A and 5-HT2C receptor agonists in the pigeon.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900150-3

7 January 2021

10.1016/S0091-3057(03)00150-3

Identifiers

DOI

1 reference

4 December 2017

1 reference